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665Abstracts
risk of future CHD events and life expectancies from the
onset of CHD. Efﬁcacy parameters came from a com-
parative Phase III trial—study 25. Demographic variables
and economic variables (costs of initiating and maintain-
ing cholesterol-lowering therapy; the costs of managing
CHD events and the costs of the drug therapy) were taken
from published sources or calculated from unit costs 
and and the frequency of use of different services. A base
case analysis was constructed from the perspective of a
55-year-old male. Extensive sensitivity analysis was con-
ducted by varying the discount rates, drug prices,
maximum percentage of beneﬁts that could be achieved,
time delay in the onset of beneﬁts, and restricting the
analysis to 10 years to allow for lack of long-term adher-
ence. RESULTS: The incremental life years saved for
rosuvastatin, atorvastatin, simvastatin, and pravastatin
compared to no treatment for a 55-year-old male with 5.5
TC/HDL cholesterol ratio were 0.40, 0.33, 0.32, and
0.26 respectively. The associated incremental costs were
£2844, £2856, £3107, and £3889. Rosuvastatin domi-
nated the three other statins in the primary prevention of
CHD, for all ages and all cholesterol levels. Sensitivity
analysis conﬁrmed the results. CONCLUSIONS: In this
quasi-Markov model, rosuvastatin was shown to be more
cost-effective for the primary prevention of CHD events
than atorvastatin, simvastatin, and pravastatin.
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OBJECTIVE: There is evidence of substantial beneﬁt in
antihypertensive combination therapy in diabetic patients
compared to monotherapy. We evaluated the combina-
tion of low dose cilazapril plus low dose doxazosin (Cz
+ Dx) versus high dose cilazapril (Cz) and versus high
dose doxazosin (Dx) in hypertensive diabetic patients in
Italy. METHODS: An incremental cost effectiveness
analysis was conducted in the societal perspective, con-
sidering Health care and indirect costs of treating for 10
years a hypothetical cohort of 1000 male diabetics, aged
50–54 years with levels of systolic blood pressure (SBP)
above 160mmHg, with Cz + Dx vs Cz vs Dx. The effects
of considered drugs in lowering blood pressure were
derived from the study by Rachmani et al (Nephron,
1998). Effectiveness was assessed in terms of morbidity
and mortality (life years gained—LYG) and quantiﬁed
using the UKPDS-36 study (Adler et al, BMJ 2000). Costs
are expressed in €2003. We report undiscounted analysis:
an analysis conducted using a discount rate of 5% for
both costs and effects led to similar results. RESULTS: Cz
+ Dx therapy showed greater efﬁcacy in reducing SBP
compared to both Cz and Dx, leading to lower morbid-
ity and to 231 LYG in the Cz + Dx cohort compared to
Cz and Dx alone. Overall cost was lower for the Cz + Dx
(€61.7 millions) cohort compared to Cz (€74.1 millions)
and Dx (€73.9 millions). CONCLUSIONS: combination
therapy with low dose cilazapril plus low dose doxazosin
dominates both high dose cilazapril and high dose doxa-
zosin in hypertensive diabetic patients in Italy, as it is both
less costly and more effective.
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OBJECTIVES: Certain combination anti-hypertensives
vary in their levels of potentially adverse metabolic effects
in patients with comorbid diabetes. We examined the
characteristics of patients initiating combination therapy
and the effects of treatment choice on direct medical
costs, using integrated medical and pharmacy claims data.
METHODS: Patients with prior evidence of diabetes who
were newly-treated for hypertension from January 1998
to March 2002 and continuously enrolled for at least 6
months before and after therapy initiation were selected.
Patients were stratiﬁed by initial ﬁxed combination 
treatment (trandolapril/verapamil [TV] vs. benazepril/
amlodipine [BA]). One-year costs of care were examined
following initiation of therapy; costs were categorized 
as cardiovascular-related and all other-related care. 95%
conﬁdence intervals for cost differences were calculated
using nonparametric bootstrapping techniques. RE-
SULTS: The mean age of the sample (n = 174) was 53
years; 47% were female. 22%, 6%, 6%, and 3% of
patients had comorbid diagnoses of hyperlipidemia,
cardiac arrhythmias, other ischemic heart disease, and
myocardial infarction respectively during pre-treatment.
Patients in the TV group had lower cardiovascular-related
cost as compared to the BA group ($2311 vs. $2570,
mean difference: -$259, 95% CI [-$2730, $1438]). Dif-
ferences in cardiovascular-related cost were manifested
primarily in the cardiovascular-related inpatient cost
($615 vs. $1,209 for TV and BA, respectively, mean dif-
ference: -$594, 95% CI [-$2900, $823]). All other-
related costs were considerably lower in the TV group
($5006 vs. $6404, mean difference: -$1397, 95% CI 
[-$9491, $3669]). Patients in the TV group ($7,317) had
lower overall costs as compared to the BA group ($8,974;
mean difference -$1,656, 95% CI [-$12,657, $4,735]).
CONCLUSIONS: Use of ﬁxed combination tran-
dolapril/verapamil therapy among patients with diabetes
is associated with reduced direct medical costs in com-
parison to combination benazepril/amlodipine.
